Editorial Comment to Treatment outcomes of sorafenib for first line or cytokine-refractory advanced renal cell carcinoma in Japanese patients

被引：1
|
作者：
Tomita, Yoshihiko [1 ]
机构：
[1] Yamagata Univ, Fac Med, Dept Urol, Yamagata 990, Japan
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2010年 / 17卷 / 09期
关键词：
D O I：
10.1111/j.1442-2042.2010.02625.x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：815 / 816
页数：2
相关论文
共 50 条
  • [1] Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients
    Ueda, Takeshi
    Imamura, Yusuke
    Komaru, Atsushi
    Fukasawa, Satoshi
    Sazuka, Tomokazu
    Suyama, Takahito
    Naya, Yukio
    Nihei, Naoki
    Ichikawa, Tomohiko
    Maruoka, Masayuki
    INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 (09) : 811 - 815
  • [2] An economic analysis of axitinib and sorafenib for second-line treatment of cytokine-refractory patients with advanced renal cell carcinoma in the United States (US)
    Oezer-Stillman, Ipek
    Ambavane, Apoorva
    Cislo, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer
    Ronald M. Bukowski
    Current Oncology Reports, 2009, 11 : 81 - 83
  • [4] Axitinib Treatment in Patients With Cytokine-Refractory Metastatic Renal Cell Cancer
    Rixe, O.
    Bukowski, R. M.
    Michaelson, M. D.
    CURRENT ONCOLOGY REPORTS, 2009, 11 (02) : 81 - 83
  • [5] IPM chemotherapy in cytokine-refractory renal cell carcinoma (RCC)
    Shamash, J
    Steele, JPC
    Wilson, P
    Nystrom, M
    Ansell, W
    Oliver, RTD
    BRITISH JOURNAL OF CANCER, 2001, 85 : 103 - 103
  • [6] Sorafenib in Patients With Metastatic Renal Cell Carcinoma Refractory to Either Sunitinib or Bevacizumab Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2011, 185 (03): : 809 - 809
  • [7] An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma
    Seiji Naito
    Taiji Tsukamoto
    Michiyuki Usami
    Hiroyuki Fujimoto
    Hideyuki Akaza
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 1065 - 1070
  • [8] An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma
    Naito, Seiji
    Tsukamoto, Taiji
    Usami, Michiyuki
    Fujimoto, Hiroyuki
    Akaza, Hideyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1065 - 1070
  • [9] Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients
    Herrmann, Edwin
    Bierer, Stefan
    Gerss, Joachim
    Koepke, Thomas
    Hertle, Lothar
    Wuelfing, Christian
    ONCOLOGY, 2008, 74 (3-4) : 216 - 222
  • [10] First-line phase II trial of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma unsuitable for cytokine treatment
    Maroto-Rey, P.
    Bellmunt, J.
    Trigo, J. M.
    Guillem, V.
    Lopez-Martin, J. A.
    Carles, J.
    Anton-Torres, A.
    Urruticoechea, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345